Fortis Healthcare

Fortis Healthcare reported a 22% year-on-year decline in net profit to Rs 197 crore for the third quarter, reflecting margin pressures and higher operating costs despite stable patient volumes. The hospital chain faced elevated input expenses and normalization effects following a strong prior-year performance. While revenues remained resilient, profitability was tempered by rising manpower costs and investment in clinical infrastructure. Analysts suggest the earnings dip highlights the sector’s sensitivity to cost inflation and competitive intensity.

Fortis Healthcare has unveiled a state-of-the-art mental healthcare facility, signaling a strategic expansion into the rapidly growing behavioral health sector. The new center aims to address increasing demand for specialized mental health services, offering comprehensive care including psychiatric evaluation, therapy, and rehabilitation. Industry experts note that rising awareness, destigmatization efforts, and growing prevalence of mental health conditions have created a pressing need for dedicated infrastructure.

The latest MSCI India Index review, effective November 26, 2025, has brought notable reshuffles to the country’s stock landscape. Paytm, Fortis Healthcare, GE Vernova T&D India, and Siemens Energy India are among the new entrants, while Tata Elxsi and Container Corporation of India (CONCOR) have been excluded. The changes have increased India’s weight in the MSCI Emerging Markets Index, prompting expectations of passive inflows worth up to US$1.5 billion (approximately Rs. 12,500 crore).

Fortis Healthcare posted a stellar performance for the first quarter of FY26, with net profit surging 57% year-on-year to Rs. 219 crore. The impressive earnings growth was backed by higher revenues from hospital services and improved efficiency across its facilities. Revenue from operations rose to Rs. 1,774 crore, reflecting the company’s ability to capitalize on rising demand for quality healthcare.

In a striking turn of events, Shivinder Mohan Singh, once a prominent figure in India’s healthcare and pharmaceutical landscape, has filed for personal insolvency under Section 94 of the Insolvency and Bankruptcy Code (IBC). His petition comes amid ongoing legal battles and a staggering Rs. 3,500 crore arbitral award owed to Japanese pharma major Daiichi Sankyo. With most of his assets either seized or significantly devalued due to prolonged litigation, Singh’s insolvency plea represents both a personal and financial reckoning years after the high-profile Ranbaxy deal unraveled.